← All trials
NCT06475131
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2024
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jun 26, 2024
- Last posted
- Aug 9, 2024
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Baili Pharmaceutical GroupLead sponsor
- Baili Pharmaceutical GroupCollaborator
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.